Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Evolus is a specialty pharmaceutical company focused on the aesthetic medicine market, primarily commercializing Jeuveau (prabotulinumtoxinA-xvfs), a botulinum toxin type A product competing directly with Allergan's Botox in the facial wrinkle treatment segment. The company operates in the US market with a direct sales force targeting dermatologists and plastic surgeons, facing intense competition from established players while attempting to gain market share through competitive pricing and provider incentive programs.
Evolus generates revenue by selling Jeuveau vials to aesthetic practitioners (dermatologists, plastic surgeons, medical spas) who administer treatments to patients seeking facial wrinkle reduction. The company competes on price positioning below Botox while maintaining 68.5% gross margins, indicating manufacturing efficiency through its Daewoong Pharmaceutical supply agreement. Revenue depends on practitioner adoption rates, patient treatment frequency (typically quarterly), and market share gains in the $3-4 billion US neurotoxin aesthetic market. The negative operating margin reflects heavy commercial infrastructure investment and ongoing legal costs related to patent litigation with Allergan/AbbVie.
Quarterly Jeuveau unit volume growth and market share gains versus Botox/Dysport
Practitioner account additions and same-provider reorder rates
Patent litigation developments with AbbVie/Allergan (ongoing infringement cases)
Gross-to-net pricing dynamics and provider incentive program costs
Path to profitability timeline and cash burn rate given negative FCF
Competitive launches (Revance's Daxxify approval impact, potential new entrants)
Patent litigation outcome with AbbVie/Allergan could result in injunctions blocking Jeuveau sales or significant damages, representing existential risk to the business model
Regulatory risk from FDA post-market surveillance or adverse event reporting that could impact product labeling or require additional clinical studies
Commoditization of neurotoxin market as multiple biosimilars and competitors enter, compressing pricing power and margins
Dependence on single manufacturing partner (Daewoong Pharmaceutical) creates supply chain concentration risk
Dominant market position of Allergan's Botox (estimated 70%+ market share) with strong brand recognition and practitioner loyalty creates high switching barriers
Revance's Daxxify (launched 2022) offers longer duration of effect (6 months vs 3-4 months), potentially superior product profile
Galderma's Dysport and potential new entrants from established pharmaceutical companies with greater resources for marketing and practitioner education
Price-based competition strategy limits ability to invest in clinical differentiation or brand building versus cash-rich competitors
Negative operating cash flow of $0.0B (near-zero) and negative FCF yield of -6.8% indicate ongoing cash consumption requiring external financing
Abnormal debt/equity ratio of -5.39 and negative book value (P/B of -9.9x) suggest complex capital structure possibly involving restructured debt or significant accumulated deficits
ROE of 483% with negative ROA of -39.3% indicates severely negative equity position, typical of companies with accumulated losses exceeding equity capital
Limited financial flexibility to weather extended period of losses or fund competitive response to new market entrants
moderate-to-high - Aesthetic neurotoxin treatments are elective, cash-pay procedures with average treatment costs of $300-600 per session. Consumer discretionary spending directly impacts treatment frequency and new patient adoption. During economic downturns or periods of reduced consumer confidence, patients may defer treatments or extend intervals between sessions. However, the aesthetic medicine market has shown resilience due to its relatively affordable luxury positioning and the established patient base with recurring treatment patterns. The company's growth trajectory is more vulnerable to macro headwinds than established players like Allergan given its need to convert new practitioners and patients.
Rising interest rates create multiple headwinds: (1) Higher discount rates compress valuation multiples for unprofitable growth companies, particularly impacting EOLS given its negative earnings and cash flow; (2) Increased financing costs for the company's debt obligations (reflected in negative debt/equity ratio suggesting complex capital structure); (3) Reduced consumer discretionary spending as mortgage and credit costs rise, potentially decreasing aesthetic treatment demand; (4) Competitive pressure as practitioners face higher working capital costs for inventory purchases. The company's path to profitability becomes more critical in a higher-rate environment where capital markets are less forgiving of cash-burning business models.
Moderate exposure through multiple channels. The company's negative operating cash flow and complex capital structure (negative debt/equity of -5.39 suggests restructured obligations or convertible instruments) make access to capital markets important for funding operations until profitability. Tightening credit conditions could impair the company's ability to refinance or raise additional capital. Additionally, aesthetic practitioners often use credit lines to purchase inventory, so restricted small business credit availability could reduce order volumes. The 2.02 current ratio provides some near-term liquidity buffer, but sustained negative FCF requires ongoing capital access.
growth/speculative - The stock attracts investors seeking high-risk, high-reward exposure to aesthetic medicine market growth with potential for significant upside if the company successfully gains market share and reaches profitability. The 31.8% revenue growth appeals to growth investors, while the -70.3% one-year return and negative profitability metrics indicate this is speculative territory. The small $0.3B market cap and high volatility (evidenced by -36.8% three-month return) attract momentum traders and biotech specialists rather than institutional value or income investors. Patent litigation outcome represents binary risk/reward scenario typical of speculative healthcare plays.
high - The stock exhibits extreme volatility as evidenced by -70.3% one-year return and -36.8% three-month decline. Multiple volatility drivers include: (1) Quarterly earnings surprises on small revenue base where modest volume misses create large percentage impacts; (2) Binary patent litigation outcomes; (3) Competitive product launches and market share shifts; (4) Small market cap and limited float amplify price movements; (5) Unprofitable business model makes valuation highly sensitive to discount rate changes and growth assumption revisions. Options market likely prices elevated implied volatility reflecting these risk factors.
